about
Getting the balance right: Established and emerging therapies for major depressive disordersMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsImportance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseInfluence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequencesWhere Failure Is Not an Option -Personalized Medicine in AstronautsSeizures associated with therapeutic doses of venlafaxine and trimipramine.Summary of information on human CYP enzymes: human P450 metabolism data.The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms.Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine.Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions.Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.Liquid chromatography tandem mass spectrometry method for the simultaneous stereoselective determination of venlafaxine and its major metabolite, O-desmethylvenlafaxine, in human plasma.Enantiomeric antidepressant drugs should be considered on individual merit.Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs.Stereo-specific LC and LC-MS bioassays of antidepressants and psychotics.Is complementary and alternative therapy effective for women in the climacteric period?Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk.Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infantsVenlafaxine extended release (XR) in the treatment of panic disorder.Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.Applicability of the Rayleigh equation for enantioselective metabolism of chiral xenobiotics by microsomes, hepatocytes and in-vivo retention in rabbit tissues.A novel prodrug strategy to improve the oral absorption of O-desmethylvenlafaxine.Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.Clinically significant drug interactions with newer antidepressants.Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.PharmGKB summary: venlafaxine pathway.Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).Venlafaxine in neuropathic pain following treatment of breast cancer.Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatment.CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis.Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer.Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration Relationships.
P2860
Q24610225-0E01406D-4011-45A2-B10B-E3239B1D6074Q24683013-1F2DC14E-A242-4818-9E0D-13549EBA3954Q27009128-E1170BEC-12B3-4B43-85BA-236F4250B26FQ28252209-3E99E905-C3C0-4D92-B81D-10D841F55646Q28544689-57E1DF13-BA3E-432E-864F-EB27660A6493Q28550427-EDEBBC3E-5D32-49C8-B51F-62B57CDBF90BQ31805799-8354B73D-FB79-40F1-94C7-1A7AE5A33AD7Q32103802-48ACB2E6-2A10-4C33-AF9A-D8BD9C512785Q33254664-ADDB4798-9F57-4CD8-9E7A-3A67F7186C80Q33538523-D3CE7ECA-06FB-4DCB-8A6C-D5677D43F16AQ34093694-DFB4DC93-F747-427B-B2DF-9CF6416DFCB6Q34272132-27073065-D253-42EB-A181-BB859413C82FQ34273354-00F7F408-E517-4D11-9770-4810D1A65909Q34481741-A7D74090-E147-4792-A743-745F420F0ABBQ34982628-9E79D08F-17AD-47C5-9855-E1E2390AAA4AQ35054997-C88F2D1D-5728-4E8B-913D-33972FA1BB66Q35376254-E53856E9-FBB5-4334-ADFB-0A1A062849E8Q35675788-233B4BAB-FBEA-48CF-A31F-30937BB30C1CQ35802378-CF7F318B-0D69-4D5C-BD91-77636AFC2040Q35804367-CEE217D0-BAB0-4BE5-82B7-07C9F2B6CD88Q35919158-27A4AB08-CF38-44EB-8935-390CA2F572BDQ36328417-703FADAC-6FBF-409B-9AED-B5FE7DB97E73Q36735906-C1C93222-9372-4EA4-839D-36AC25B21035Q37204088-EE305B50-6058-4A18-BE95-EC921B2FFBECQ37808483-1135BDCD-B75A-4C5B-9538-4902FB0D53A5Q37845170-25E9D844-49A0-4E21-90F0-8F2C00161E67Q37968621-3DBBD905-A0E5-4911-A7F1-B7D231BB3CA3Q38017920-42B0C38E-6C2B-4ACF-8BDC-EC95F10F1407Q38103593-450EACFC-9C22-418B-BCA3-BB391C74B2BBQ38152886-6E279939-938B-45A9-B001-861E2C49950AQ38255420-80CD053F-75E9-4D4E-9911-CCEF4F1E1BE3Q39409556-F4284D96-228B-4F3B-9DD6-F2BC34DC89FCQ41593701-3FCDFA70-25EB-45B8-BBCD-FE8DBA7F3797Q43556050-EE4F8EE9-5670-430B-AC9D-D5051B441398Q43576840-9F904C17-AF6D-457F-8D75-B3AF361B0374Q43968191-FDC3F3F2-ACC1-434F-8142-36B431A183C7Q44784776-30713439-D70B-4E58-B66A-48F97B93887EQ45176540-79CE536E-FED9-4774-8D54-A89877557AD1Q47151234-DA467573-F0A9-42AF-94E7-C8AEB61D167DQ47397651-5923C79A-1E4D-40E3-9AE4-9F945A19CEF2
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Venlafaxine oxidation in vitro is catalysed by CYP2D6.
@en
Venlafaxine oxidation in vitro is catalysed by CYP2D6.
@nl
type
label
Venlafaxine oxidation in vitro is catalysed by CYP2D6.
@en
Venlafaxine oxidation in vitro is catalysed by CYP2D6.
@nl
prefLabel
Venlafaxine oxidation in vitro is catalysed by CYP2D6.
@en
Venlafaxine oxidation in vitro is catalysed by CYP2D6.
@nl
P2093
P2860
P1476
Venlafaxine oxidation in vitro is catalysed by CYP2D6.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1996.TB00173.X
P407
P577
1996-02-01T00:00:00Z